The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer

Steven E. Schild, William W. Wong, Sujay A. Vora, Michele Y. Halyard, Donald W Northfelt, Heidi L. Kogut, Richard H. Wheeler

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: This analysis was performed to determine the long-term results of a Phase I trial that included 3-times-a-day radiotherapy (TIDRT) and concurrent daily cisplatin (CDDP) for Stage III non-small-cell lung cancer. Methods and Materials: Twenty patients with Stage III non-small-cell lung cancer were treated with TIDRT delivered over 12 weekdays that included 57.6 Gy administered in 1.5 Gy fractions at 8 a.m. and 4 p.m., and 1.8 Gy fractions at noon. AP-PA fields were used at 8 a.m. and 4 p.m. Opposed oblique off cord fields were used at noon. The first 5 patients were given no CDDP, the second 5 patients received 5 mg/m2 of CDDP, and the remaining 10 patients received 7.5 mg/m2 of CDDP. All survivors were followed for greater than 5 years. Results: The maximum tolerated dose of daily CDDP during this program of radiation therapy was 7.5 mg/m2. None of the patients died as a result of toxicity. The median survival was 19.2 months, and the 5-year survival rate was 25%. Tumor response and patterns of failure were also evaluated. Conclusions: This study was performed to determine the maximum tolerated dose of CDDP when administered daily during an aggressive program of TIDRT. The survival results were promising, suggesting that the combination of TIDRT and systemic therapy deserves further study.

Original languageEnglish (US)
Pages (from-to)1432-1437
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume62
Issue number5
DOIs
StatePublished - Aug 1 2005

Fingerprint

Non-Small Cell Lung Carcinoma
lungs
Cisplatin
radiation therapy
Radiotherapy
cancer
dosage
noon
Maximum Tolerated Dose
Round Ligaments
Survival
toxicity
Survivors
therapy
tumors
Survival Rate
Neoplasms
Therapeutics

Keywords

  • Cisplatin
  • Combined modality therapy
  • Hyperfractionated radiation therapy
  • Non-small-cell lung cancer
  • Three-times-a-day RT

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. / Schild, Steven E.; Wong, William W.; Vora, Sujay A.; Halyard, Michele Y.; Northfelt, Donald W; Kogut, Heidi L.; Wheeler, Richard H.

In: International Journal of Radiation Oncology Biology Physics, Vol. 62, No. 5, 01.08.2005, p. 1432-1437.

Research output: Contribution to journalArticle

Schild, Steven E. ; Wong, William W. ; Vora, Sujay A. ; Halyard, Michele Y. ; Northfelt, Donald W ; Kogut, Heidi L. ; Wheeler, Richard H. / The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. In: International Journal of Radiation Oncology Biology Physics. 2005 ; Vol. 62, No. 5. pp. 1432-1437.
@article{7337677a9d69485fa1c3dea29d79312e,
title = "The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer",
abstract = "Purpose: This analysis was performed to determine the long-term results of a Phase I trial that included 3-times-a-day radiotherapy (TIDRT) and concurrent daily cisplatin (CDDP) for Stage III non-small-cell lung cancer. Methods and Materials: Twenty patients with Stage III non-small-cell lung cancer were treated with TIDRT delivered over 12 weekdays that included 57.6 Gy administered in 1.5 Gy fractions at 8 a.m. and 4 p.m., and 1.8 Gy fractions at noon. AP-PA fields were used at 8 a.m. and 4 p.m. Opposed oblique off cord fields were used at noon. The first 5 patients were given no CDDP, the second 5 patients received 5 mg/m2 of CDDP, and the remaining 10 patients received 7.5 mg/m2 of CDDP. All survivors were followed for greater than 5 years. Results: The maximum tolerated dose of daily CDDP during this program of radiation therapy was 7.5 mg/m2. None of the patients died as a result of toxicity. The median survival was 19.2 months, and the 5-year survival rate was 25{\%}. Tumor response and patterns of failure were also evaluated. Conclusions: This study was performed to determine the maximum tolerated dose of CDDP when administered daily during an aggressive program of TIDRT. The survival results were promising, suggesting that the combination of TIDRT and systemic therapy deserves further study.",
keywords = "Cisplatin, Combined modality therapy, Hyperfractionated radiation therapy, Non-small-cell lung cancer, Three-times-a-day RT",
author = "Schild, {Steven E.} and Wong, {William W.} and Vora, {Sujay A.} and Halyard, {Michele Y.} and Northfelt, {Donald W} and Kogut, {Heidi L.} and Wheeler, {Richard H.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.ijrobp.2005.01.003",
language = "English (US)",
volume = "62",
pages = "1432--1437",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer

AU - Schild, Steven E.

AU - Wong, William W.

AU - Vora, Sujay A.

AU - Halyard, Michele Y.

AU - Northfelt, Donald W

AU - Kogut, Heidi L.

AU - Wheeler, Richard H.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Purpose: This analysis was performed to determine the long-term results of a Phase I trial that included 3-times-a-day radiotherapy (TIDRT) and concurrent daily cisplatin (CDDP) for Stage III non-small-cell lung cancer. Methods and Materials: Twenty patients with Stage III non-small-cell lung cancer were treated with TIDRT delivered over 12 weekdays that included 57.6 Gy administered in 1.5 Gy fractions at 8 a.m. and 4 p.m., and 1.8 Gy fractions at noon. AP-PA fields were used at 8 a.m. and 4 p.m. Opposed oblique off cord fields were used at noon. The first 5 patients were given no CDDP, the second 5 patients received 5 mg/m2 of CDDP, and the remaining 10 patients received 7.5 mg/m2 of CDDP. All survivors were followed for greater than 5 years. Results: The maximum tolerated dose of daily CDDP during this program of radiation therapy was 7.5 mg/m2. None of the patients died as a result of toxicity. The median survival was 19.2 months, and the 5-year survival rate was 25%. Tumor response and patterns of failure were also evaluated. Conclusions: This study was performed to determine the maximum tolerated dose of CDDP when administered daily during an aggressive program of TIDRT. The survival results were promising, suggesting that the combination of TIDRT and systemic therapy deserves further study.

AB - Purpose: This analysis was performed to determine the long-term results of a Phase I trial that included 3-times-a-day radiotherapy (TIDRT) and concurrent daily cisplatin (CDDP) for Stage III non-small-cell lung cancer. Methods and Materials: Twenty patients with Stage III non-small-cell lung cancer were treated with TIDRT delivered over 12 weekdays that included 57.6 Gy administered in 1.5 Gy fractions at 8 a.m. and 4 p.m., and 1.8 Gy fractions at noon. AP-PA fields were used at 8 a.m. and 4 p.m. Opposed oblique off cord fields were used at noon. The first 5 patients were given no CDDP, the second 5 patients received 5 mg/m2 of CDDP, and the remaining 10 patients received 7.5 mg/m2 of CDDP. All survivors were followed for greater than 5 years. Results: The maximum tolerated dose of daily CDDP during this program of radiation therapy was 7.5 mg/m2. None of the patients died as a result of toxicity. The median survival was 19.2 months, and the 5-year survival rate was 25%. Tumor response and patterns of failure were also evaluated. Conclusions: This study was performed to determine the maximum tolerated dose of CDDP when administered daily during an aggressive program of TIDRT. The survival results were promising, suggesting that the combination of TIDRT and systemic therapy deserves further study.

KW - Cisplatin

KW - Combined modality therapy

KW - Hyperfractionated radiation therapy

KW - Non-small-cell lung cancer

KW - Three-times-a-day RT

UR - http://www.scopus.com/inward/record.url?scp=22144496750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144496750&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.01.003

DO - 10.1016/j.ijrobp.2005.01.003

M3 - Article

C2 - 16029804

AN - SCOPUS:22144496750

VL - 62

SP - 1432

EP - 1437

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -